nodes	percent_of_prediction	percent_of_DWPC	metapath
Dobutamine—COMT—prostate cancer	0.361	0.651	CbGaD
Dobutamine—COMT—Conjugated Estrogens—prostate cancer	0.267	1	CbGbCtD
Dobutamine—ADRB2—prostate cancer	0.193	0.349	CbGaD
Dobutamine—Skin exfoliation—Estramustine—prostate cancer	0.00263	0.0342	CcSEcCtD
Dobutamine—Skin necrosis—Etoposide—prostate cancer	0.00216	0.0281	CcSEcCtD
Dobutamine—Hypokalaemia—Abiraterone—prostate cancer	0.00176	0.023	CcSEcCtD
Dobutamine—CA5B—prostate gland—prostate cancer	0.00151	0.101	CbGeAlD
Dobutamine—Angina pectoris—Nilutamide—prostate cancer	0.00149	0.0195	CcSEcCtD
Dobutamine—COMT—prostate gland—prostate cancer	0.00139	0.0928	CbGeAlD
Dobutamine—Hypokalaemia—Cabazitaxel—prostate cancer	0.00136	0.0177	CcSEcCtD
Dobutamine—Skin necrosis—Epirubicin—prostate cancer	0.00121	0.0158	CcSEcCtD
Dobutamine—Masoprocol—IGF1R—prostate cancer	0.0012	0.216	CrCbGaD
Dobutamine—ADRB1—prostate gland—prostate cancer	0.00118	0.0786	CbGeAlD
Dobutamine—COMT—seminal vesicle—prostate cancer	0.00118	0.0785	CbGeAlD
Dobutamine—Skin necrosis—Doxorubicin—prostate cancer	0.00112	0.0146	CcSEcCtD
Dobutamine—Angina pectoris—Bicalutamide—prostate cancer	0.00108	0.014	CcSEcCtD
Dobutamine—Ventricular extrasystoles—Estradiol—prostate cancer	0.00108	0.014	CcSEcCtD
Dobutamine—Chest pain—Estramustine—prostate cancer	0.00102	0.0134	CcSEcCtD
Dobutamine—Phlebitis—Conjugated Estrogens—prostate cancer	0.00102	0.0133	CcSEcCtD
Dobutamine—CA5B—urethra—prostate cancer	0.00101	0.0675	CbGeAlD
Dobutamine—Chest pain—Abiraterone—prostate cancer	0.000994	0.013	CcSEcCtD
Dobutamine—Thrombocytopenia—Estramustine—prostate cancer	0.000961	0.0125	CcSEcCtD
Dobutamine—COMT—renal system—prostate cancer	0.000949	0.0632	CbGeAlD
Dobutamine—COMT—urethra—prostate cancer	0.000932	0.0621	CbGeAlD
Dobutamine—Skin exfoliation—Estradiol—prostate cancer	0.000928	0.0121	CcSEcCtD
Dobutamine—Chest pain—Nilutamide—prostate cancer	0.000908	0.0118	CcSEcCtD
Dobutamine—Palpitations—Estradiol valerate/Dienogest—prostate cancer	0.000886	0.0116	CcSEcCtD
Dobutamine—Dyspnoea—Estramustine—prostate cancer	0.000875	0.0114	CcSEcCtD
Dobutamine—CA2—prostate gland—prostate cancer	0.000865	0.0577	CbGeAlD
Dobutamine—Dyspnoea—Abiraterone—prostate cancer	0.00085	0.0111	CcSEcCtD
Dobutamine—Thrombocytopenia—Flutamide—prostate cancer	0.000849	0.0111	CcSEcCtD
Dobutamine—Palpitations—Degarelix—prostate cancer	0.000842	0.011	CcSEcCtD
Dobutamine—Phlebitis—Estradiol—prostate cancer	0.000819	0.0107	CcSEcCtD
Dobutamine—Hypokalaemia—Conjugated Estrogens—prostate cancer	0.000802	0.0105	CcSEcCtD
Dobutamine—Dyspnoea—Nilutamide—prostate cancer	0.000776	0.0101	CcSEcCtD
Dobutamine—Chest pain—Cabazitaxel—prostate cancer	0.000764	0.00997	CcSEcCtD
Dobutamine—Phlebitis—Mitoxantrone—prostate cancer	0.000763	0.00995	CcSEcCtD
Dobutamine—Angina pectoris—Goserelin—prostate cancer	0.000749	0.00977	CcSEcCtD
Dobutamine—CA2—seminal vesicle—prostate cancer	0.000732	0.0488	CbGeAlD
Dobutamine—Hypotension—Degarelix—prostate cancer	0.000727	0.00948	CcSEcCtD
Dobutamine—Skin exfoliation—Etoposide—prostate cancer	0.000719	0.00938	CcSEcCtD
Dobutamine—Thrombocytopenia—Cabazitaxel—prostate cancer	0.000717	0.00936	CcSEcCtD
Dobutamine—COMT—bone marrow—prostate cancer	0.000717	0.0478	CbGeAlD
Dobutamine—Tachycardia—Cabazitaxel—prostate cancer	0.000715	0.00933	CcSEcCtD
Dobutamine—Pruritus—Estramustine—prostate cancer	0.000694	0.00905	CcSEcCtD
Dobutamine—Dyspnoea—Degarelix—prostate cancer	0.000693	0.00904	CcSEcCtD
Dobutamine—Hypotension—Cabazitaxel—prostate cancer	0.000685	0.00893	CcSEcCtD
Dobutamine—Ventricular extrasystoles—Capecitabine—prostate cancer	0.000671	0.00875	CcSEcCtD
Dobutamine—CA5B—testis—prostate cancer	0.000666	0.0444	CbGeAlD
Dobutamine—Pruritus—Estrone—prostate cancer	0.000663	0.00865	CcSEcCtD
Dobutamine—Chest pain—Bicalutamide—prostate cancer	0.000656	0.00855	CcSEcCtD
Dobutamine—Dyspnoea—Cabazitaxel—prostate cancer	0.000653	0.00852	CcSEcCtD
Dobutamine—CA2—epithelium—prostate cancer	0.000636	0.0424	CbGeAlD
Dobutamine—Phlebitis—Etoposide—prostate cancer	0.000634	0.00827	CcSEcCtD
Dobutamine—Pruritus—Nilutamide—prostate cancer	0.000616	0.00803	CcSEcCtD
Dobutamine—Thrombocytopenia—Bicalutamide—prostate cancer	0.000615	0.00803	CcSEcCtD
Dobutamine—Headache—Estramustine—prostate cancer	0.000615	0.00802	CcSEcCtD
Dobutamine—Pruritus—Flutamide—prostate cancer	0.000613	0.008	CcSEcCtD
Dobutamine—COMT—testis—prostate cancer	0.000613	0.0409	CbGeAlD
Dobutamine—Hypokalaemia—Mitoxantrone—prostate cancer	0.000598	0.0078	CcSEcCtD
Dobutamine—Skin exfoliation—Docetaxel—prostate cancer	0.000597	0.00779	CcSEcCtD
Dobutamine—CA2—renal system—prostate cancer	0.000589	0.0393	CbGeAlD
Dobutamine—Headache—Estrone—prostate cancer	0.000587	0.00766	CcSEcCtD
Dobutamine—Nausea—Estramustine—prostate cancer	0.000583	0.0076	CcSEcCtD
Dobutamine—Pruritus—Estradiol valerate/Dienogest—prostate cancer	0.000579	0.00755	CcSEcCtD
Dobutamine—Skin exfoliation—Capecitabine—prostate cancer	0.000578	0.00754	CcSEcCtD
Dobutamine—Dyspnoea—Bicalutamide—prostate cancer	0.00056	0.00731	CcSEcCtD
Dobutamine—Nausea—Estrone—prostate cancer	0.000557	0.00726	CcSEcCtD
Dobutamine—Pruritus—Degarelix—prostate cancer	0.00055	0.00718	CcSEcCtD
Dobutamine—Headache—Nilutamide—prostate cancer	0.000545	0.00711	CcSEcCtD
Dobutamine—Headache—Flutamide—prostate cancer	0.000543	0.00708	CcSEcCtD
Dobutamine—Phlebitis—Docetaxel—prostate cancer	0.000527	0.00688	CcSEcCtD
Dobutamine—Nausea—Nilutamide—prostate cancer	0.000517	0.00675	CcSEcCtD
Dobutamine—Skin exfoliation—Prednisone—prostate cancer	0.000515	0.00672	CcSEcCtD
Dobutamine—Nausea—Flutamide—prostate cancer	0.000515	0.00672	CcSEcCtD
Dobutamine—Headache—Estradiol valerate/Dienogest—prostate cancer	0.000513	0.00668	CcSEcCtD
Dobutamine—Phlebitis—Capecitabine—prostate cancer	0.000511	0.00666	CcSEcCtD
Dobutamine—Headache—Degarelix—prostate cancer	0.000487	0.00636	CcSEcCtD
Dobutamine—Nausea—Estradiol valerate/Dienogest—prostate cancer	0.000486	0.00634	CcSEcCtD
Dobutamine—CA5B—lymph node—prostate cancer	0.000483	0.0322	CbGeAlD
Dobutamine—Palpitations—Goserelin—prostate cancer	0.000473	0.00617	CcSEcCtD
Dobutamine—Palpitations—Conjugated Estrogens—prostate cancer	0.000469	0.00612	CcSEcCtD
Dobutamine—Ventricular extrasystoles—Epirubicin—prostate cancer	0.000467	0.00609	CcSEcCtD
Dobutamine—Nausea—Degarelix—prostate cancer	0.000462	0.00603	CcSEcCtD
Dobutamine—Headache—Cabazitaxel—prostate cancer	0.000459	0.00599	CcSEcCtD
Dobutamine—Chest pain—Goserelin—prostate cancer	0.000456	0.00595	CcSEcCtD
Dobutamine—Chest pain—Conjugated Estrogens—prostate cancer	0.000452	0.00589	CcSEcCtD
Dobutamine—CA2—bone marrow—prostate cancer	0.000446	0.0297	CbGeAlD
Dobutamine—Pruritus—Bicalutamide—prostate cancer	0.000445	0.0058	CcSEcCtD
Dobutamine—COMT—lymph node—prostate cancer	0.000444	0.0296	CbGeAlD
Dobutamine—Nausea—Cabazitaxel—prostate cancer	0.000435	0.00568	CcSEcCtD
Dobutamine—Ventricular extrasystoles—Doxorubicin—prostate cancer	0.000432	0.00564	CcSEcCtD
Dobutamine—Thrombocytopenia—Goserelin—prostate cancer	0.000428	0.00558	CcSEcCtD
Dobutamine—Tachycardia—Goserelin—prostate cancer	0.000427	0.00557	CcSEcCtD
Dobutamine—Tachycardia—Conjugated Estrogens—prostate cancer	0.000423	0.00551	CcSEcCtD
Dobutamine—Hypotension—Goserelin—prostate cancer	0.000409	0.00533	CcSEcCtD
Dobutamine—Hypotension—Conjugated Estrogens—prostate cancer	0.000405	0.00528	CcSEcCtD
Dobutamine—Skin exfoliation—Epirubicin—prostate cancer	0.000403	0.00526	CcSEcCtD
Dobutamine—Hypokalaemia—Capecitabine—prostate cancer	0.0004	0.00522	CcSEcCtD
Dobutamine—Headache—Bicalutamide—prostate cancer	0.000394	0.00514	CcSEcCtD
Dobutamine—Dyspnoea—Goserelin—prostate cancer	0.00039	0.00508	CcSEcCtD
Dobutamine—Dyspnoea—Conjugated Estrogens—prostate cancer	0.000386	0.00504	CcSEcCtD
Dobutamine—Angina pectoris—Docetaxel—prostate cancer	0.000382	0.00499	CcSEcCtD
Dobutamine—CA2—testis—prostate cancer	0.000381	0.0254	CbGeAlD
Dobutamine—Masoprocol—CYP19A1—prostate cancer	0.000379	0.0683	CrCbGaD
Dobutamine—Pruritus—Ethinyl Estradiol—prostate cancer	0.000376	0.0049	CcSEcCtD
Dobutamine—Palpitations—Estradiol—prostate cancer	0.000375	0.0049	CcSEcCtD
Dobutamine—Nausea—Bicalutamide—prostate cancer	0.000373	0.00487	CcSEcCtD
Dobutamine—Skin exfoliation—Doxorubicin—prostate cancer	0.000373	0.00486	CcSEcCtD
Dobutamine—Angina pectoris—Capecitabine—prostate cancer	0.00037	0.00483	CcSEcCtD
Dobutamine—Arformoterol—CYP2A6—prostate cancer	0.00037	0.0667	CrCbGaD
Dobutamine—Formoterol—CYP2A6—prostate cancer	0.00037	0.0667	CrCbGaD
Dobutamine—Chest pain—Estradiol—prostate cancer	0.000362	0.00472	CcSEcCtD
Dobutamine—Hypokalaemia—Prednisone—prostate cancer	0.000357	0.00465	CcSEcCtD
Dobutamine—Phlebitis—Epirubicin—prostate cancer	0.000356	0.00464	CcSEcCtD
Dobutamine—Tachycardia—Estradiol—prostate cancer	0.000338	0.00441	CcSEcCtD
Dobutamine—Chest pain—Mitoxantrone—prostate cancer	0.000337	0.00439	CcSEcCtD
Dobutamine—Headache—Ethinyl Estradiol—prostate cancer	0.000333	0.00434	CcSEcCtD
Dobutamine—Ritodrine—ADRB2—prostate cancer	0.000333	0.06	CrCbGaD
Dobutamine—Fenoterol—ADRB2—prostate cancer	0.000333	0.06	CrCbGaD
Dobutamine—Phlebitis—Doxorubicin—prostate cancer	0.000329	0.00429	CcSEcCtD
Dobutamine—Thrombocytopenia—Mitoxantrone—prostate cancer	0.000316	0.00412	CcSEcCtD
Dobutamine—Nausea—Ethinyl Estradiol—prostate cancer	0.000316	0.00412	CcSEcCtD
Dobutamine—Tachycardia—Mitoxantrone—prostate cancer	0.000315	0.00411	CcSEcCtD
Dobutamine—Arbutamine—ADRB2—prostate cancer	0.000311	0.0561	CrCbGaD
Dobutamine—Pruritus—Goserelin—prostate cancer	0.000309	0.00403	CcSEcCtD
Dobutamine—Dyspnoea—Estradiol—prostate cancer	0.000309	0.00403	CcSEcCtD
Dobutamine—Pruritus—Conjugated Estrogens—prostate cancer	0.000306	0.004	CcSEcCtD
Dobutamine—Dopamine—SLC22A3—prostate cancer	0.000306	0.0551	CrCbGaD
Dobutamine—Arformoterol—ADRB2—prostate cancer	0.000302	0.0545	CrCbGaD
Dobutamine—Formoterol—ADRB2—prostate cancer	0.000302	0.0545	CrCbGaD
Dobutamine—Hypotension—Mitoxantrone—prostate cancer	0.000302	0.00394	CcSEcCtD
Dobutamine—Dyspnoea—Mitoxantrone—prostate cancer	0.000288	0.00376	CcSEcCtD
Dobutamine—Chest pain—Etoposide—prostate cancer	0.00028	0.00366	CcSEcCtD
Dobutamine—Hypokalaemia—Epirubicin—prostate cancer	0.000279	0.00364	CcSEcCtD
Dobutamine—CA2—lymph node—prostate cancer	0.000276	0.0184	CbGeAlD
Dobutamine—Headache—Goserelin—prostate cancer	0.000274	0.00357	CcSEcCtD
Dobutamine—Headache—Conjugated Estrogens—prostate cancer	0.000271	0.00354	CcSEcCtD
Dobutamine—Thrombocytopenia—Etoposide—prostate cancer	0.000263	0.00343	CcSEcCtD
Dobutamine—Tachycardia—Etoposide—prostate cancer	0.000262	0.00342	CcSEcCtD
Dobutamine—Dopamine—COMT—prostate cancer	0.000261	0.0471	CrCbGaD
Dobutamine—Arformoterol—CYP2C19—prostate cancer	0.00026	0.0469	CrCbGaD
Dobutamine—Formoterol—CYP2C19—prostate cancer	0.00026	0.0469	CrCbGaD
Dobutamine—Nausea—Goserelin—prostate cancer	0.00026	0.00339	CcSEcCtD
Dobutamine—Hypokalaemia—Doxorubicin—prostate cancer	0.000258	0.00337	CcSEcCtD
Dobutamine—Angina pectoris—Epirubicin—prostate cancer	0.000258	0.00336	CcSEcCtD
Dobutamine—Nausea—Conjugated Estrogens—prostate cancer	0.000257	0.00336	CcSEcCtD
Dobutamine—Hypotension—Etoposide—prostate cancer	0.000251	0.00327	CcSEcCtD
Dobutamine—Pruritus—Estradiol—prostate cancer	0.000245	0.0032	CcSEcCtD
Dobutamine—Palpitations—Docetaxel—prostate cancer	0.000242	0.00315	CcSEcCtD
Dobutamine—Dyspnoea—Etoposide—prostate cancer	0.00024	0.00312	CcSEcCtD
Dobutamine—Angina pectoris—Doxorubicin—prostate cancer	0.000239	0.00311	CcSEcCtD
Dobutamine—Palpitations—Capecitabine—prostate cancer	0.000234	0.00305	CcSEcCtD
Dobutamine—Chest pain—Docetaxel—prostate cancer	0.000233	0.00304	CcSEcCtD
Dobutamine—Chest pain—Capecitabine—prostate cancer	0.000226	0.00294	CcSEcCtD
Dobutamine—Labetalol—ADRB2—prostate cancer	0.000221	0.0398	CrCbGaD
Dobutamine—Dopamine—SLC22A1—prostate cancer	0.000219	0.0395	CrCbGaD
Dobutamine—Thrombocytopenia—Docetaxel—prostate cancer	0.000219	0.00285	CcSEcCtD
Dobutamine—Tachycardia—Docetaxel—prostate cancer	0.000218	0.00284	CcSEcCtD
Dobutamine—Headache—Estradiol—prostate cancer	0.000217	0.00283	CcSEcCtD
Dobutamine—Thrombocytopenia—Capecitabine—prostate cancer	0.000212	0.00276	CcSEcCtD
Dobutamine—Tachycardia—Capecitabine—prostate cancer	0.000211	0.00275	CcSEcCtD
Dobutamine—Hypotension—Docetaxel—prostate cancer	0.000209	0.00272	CcSEcCtD
Dobutamine—Nausea—Estradiol—prostate cancer	0.000206	0.00269	CcSEcCtD
Dobutamine—Headache—Mitoxantrone—prostate cancer	0.000202	0.00264	CcSEcCtD
Dobutamine—Hypotension—Capecitabine—prostate cancer	0.000202	0.00263	CcSEcCtD
Dobutamine—Dyspnoea—Docetaxel—prostate cancer	0.000199	0.0026	CcSEcCtD
Dobutamine—Dyspnoea—Capecitabine—prostate cancer	0.000193	0.00251	CcSEcCtD
Dobutamine—Nausea—Mitoxantrone—prostate cancer	0.000192	0.0025	CcSEcCtD
Dobutamine—Pruritus—Etoposide—prostate cancer	0.00019	0.00248	CcSEcCtD
Dobutamine—Tachycardia—Prednisone—prostate cancer	0.000188	0.00245	CcSEcCtD
Dobutamine—Headache—Etoposide—prostate cancer	0.000168	0.0022	CcSEcCtD
Dobutamine—Palpitations—Epirubicin—prostate cancer	0.000163	0.00213	CcSEcCtD
Dobutamine—Nausea—Etoposide—prostate cancer	0.00016	0.00208	CcSEcCtD
Dobutamine—Pruritus—Docetaxel—prostate cancer	0.000158	0.00206	CcSEcCtD
Dobutamine—Chest pain—Epirubicin—prostate cancer	0.000157	0.00205	CcSEcCtD
Dobutamine—Pruritus—Capecitabine—prostate cancer	0.000153	0.00199	CcSEcCtD
Dobutamine—Palpitations—Doxorubicin—prostate cancer	0.000151	0.00197	CcSEcCtD
Dobutamine—Thrombocytopenia—Epirubicin—prostate cancer	0.000147	0.00192	CcSEcCtD
Dobutamine—Tachycardia—Epirubicin—prostate cancer	0.000147	0.00192	CcSEcCtD
Dobutamine—Chest pain—Doxorubicin—prostate cancer	0.000145	0.0019	CcSEcCtD
Dobutamine—Hypotension—Epirubicin—prostate cancer	0.000141	0.00184	CcSEcCtD
Dobutamine—Headache—Docetaxel—prostate cancer	0.00014	0.00182	CcSEcCtD
Dobutamine—Thrombocytopenia—Doxorubicin—prostate cancer	0.000136	0.00178	CcSEcCtD
Dobutamine—Pruritus—Prednisone—prostate cancer	0.000136	0.00178	CcSEcCtD
Dobutamine—Tachycardia—Doxorubicin—prostate cancer	0.000136	0.00177	CcSEcCtD
Dobutamine—Headache—Capecitabine—prostate cancer	0.000135	0.00177	CcSEcCtD
Dobutamine—Dyspnoea—Epirubicin—prostate cancer	0.000134	0.00175	CcSEcCtD
Dobutamine—Nausea—Docetaxel—prostate cancer	0.000133	0.00173	CcSEcCtD
Dobutamine—Hypotension—Doxorubicin—prostate cancer	0.00013	0.0017	CcSEcCtD
Dobutamine—Nausea—Capecitabine—prostate cancer	0.000128	0.00167	CcSEcCtD
Dobutamine—Dyspnoea—Doxorubicin—prostate cancer	0.000124	0.00162	CcSEcCtD
Dobutamine—Headache—Prednisone—prostate cancer	0.000121	0.00157	CcSEcCtD
Dobutamine—Dopamine—CYP2C19—prostate cancer	0.00012	0.0217	CrCbGaD
Dobutamine—Nausea—Prednisone—prostate cancer	0.000114	0.00149	CcSEcCtD
Dobutamine—Pruritus—Epirubicin—prostate cancer	0.000107	0.00139	CcSEcCtD
Dobutamine—Pruritus—Doxorubicin—prostate cancer	9.86e-05	0.00129	CcSEcCtD
Dobutamine—Headache—Epirubicin—prostate cancer	9.43e-05	0.00123	CcSEcCtD
Dobutamine—Nausea—Epirubicin—prostate cancer	8.95e-05	0.00117	CcSEcCtD
Dobutamine—Headache—Doxorubicin—prostate cancer	8.73e-05	0.00114	CcSEcCtD
Dobutamine—Nausea—Doxorubicin—prostate cancer	8.28e-05	0.00108	CcSEcCtD
Dobutamine—CA5A—Metabolism—PTEN—prostate cancer	1.53e-05	0.000189	CbGpPWpGaD
Dobutamine—CA2—Metabolism—PIK3CG—prostate cancer	1.53e-05	0.000189	CbGpPWpGaD
Dobutamine—COMT—Metabolism—MTHFR—prostate cancer	1.53e-05	0.000188	CbGpPWpGaD
Dobutamine—ADRB1—GPCR downstream signaling—ITPR1—prostate cancer	1.52e-05	0.000188	CbGpPWpGaD
Dobutamine—ADRB2—Signaling by GPCR—PRKCQ—prostate cancer	1.52e-05	0.000188	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—VIP—prostate cancer	1.51e-05	0.000186	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—GNRH1—prostate cancer	1.51e-05	0.000186	CbGpPWpGaD
Dobutamine—COMT—Metabolism—PPARA—prostate cancer	1.5e-05	0.000185	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—LPAR1—prostate cancer	1.5e-05	0.000185	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—GRP—prostate cancer	1.5e-05	0.000185	CbGpPWpGaD
Dobutamine—ADRB2—GPCR downstream signaling—ITPR1—prostate cancer	1.49e-05	0.000184	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—PLCB2—prostate cancer	1.48e-05	0.000183	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—LRP2—prostate cancer	1.48e-05	0.000183	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—LPAR1—prostate cancer	1.46e-05	0.000181	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—GRP—prostate cancer	1.46e-05	0.000181	CbGpPWpGaD
Dobutamine—ADRB1—Signaling by GPCR—ADRB2—prostate cancer	1.46e-05	0.00018	CbGpPWpGaD
Dobutamine—CA5A—Metabolism—EP300—prostate cancer	1.46e-05	0.00018	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—P4HB—prostate cancer	1.45e-05	0.000179	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—CX3CL1—prostate cancer	1.45e-05	0.000179	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—PLCB2—prostate cancer	1.45e-05	0.000179	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—LRP2—prostate cancer	1.45e-05	0.000179	CbGpPWpGaD
Dobutamine—CA2—Metabolism—INS—prostate cancer	1.45e-05	0.000179	CbGpPWpGaD
Dobutamine—CA5B—Metabolism—PTEN—prostate cancer	1.43e-05	0.000176	CbGpPWpGaD
Dobutamine—ADRB1—Signaling by GPCR—VAV3—prostate cancer	1.43e-05	0.000176	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—HIST1H2BG—prostate cancer	1.43e-05	0.000176	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—CX3CL1—prostate cancer	1.42e-05	0.000175	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—P4HB—prostate cancer	1.42e-05	0.000175	CbGpPWpGaD
Dobutamine—CA2—Metabolism—CREBBP—prostate cancer	1.42e-05	0.000175	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—GRB7—prostate cancer	1.41e-05	0.000174	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—PDE4D—prostate cancer	1.41e-05	0.000174	CbGpPWpGaD
Dobutamine—COMT—Metabolism—CAV1—prostate cancer	1.41e-05	0.000174	CbGpPWpGaD
Dobutamine—ADRB2—Signaling by GPCR—VAV3—prostate cancer	1.4e-05	0.000172	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—HIST1H2BG—prostate cancer	1.4e-05	0.000172	CbGpPWpGaD
Dobutamine—ADRB1—Signaling by GPCR—ITPR1—prostate cancer	1.38e-05	0.000171	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—GRB7—prostate cancer	1.38e-05	0.000171	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—PDE4D—prostate cancer	1.38e-05	0.000171	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—HIST1H4H—prostate cancer	1.38e-05	0.00017	CbGpPWpGaD
Dobutamine—ADRB1—GPCR ligand binding—CXCL8—prostate cancer	1.38e-05	0.00017	CbGpPWpGaD
Dobutamine—CA5B—Metabolism—EP300—prostate cancer	1.36e-05	0.000168	CbGpPWpGaD
Dobutamine—ADRB2—Signaling by GPCR—ITPR1—prostate cancer	1.35e-05	0.000167	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—HIST1H4H—prostate cancer	1.35e-05	0.000166	CbGpPWpGaD
Dobutamine—ADRB2—GPCR ligand binding—CXCL8—prostate cancer	1.35e-05	0.000166	CbGpPWpGaD
Dobutamine—CA2—Metabolism—PIK3CD—prostate cancer	1.35e-05	0.000166	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—GNG5—prostate cancer	1.34e-05	0.000166	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—GNG5—prostate cancer	1.32e-05	0.000162	CbGpPWpGaD
Dobutamine—COMT—Metabolism—PIK3CG—prostate cancer	1.28e-05	0.000158	CbGpPWpGaD
Dobutamine—CA2—Metabolism—NOS3—prostate cancer	1.27e-05	0.000157	CbGpPWpGaD
Dobutamine—COMT—Metabolism—INS—prostate cancer	1.21e-05	0.00015	CbGpPWpGaD
Dobutamine—COMT—Metabolism—CREBBP—prostate cancer	1.19e-05	0.000147	CbGpPWpGaD
Dobutamine—CA2—Metabolism—PIK3CB—prostate cancer	1.17e-05	0.000145	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—PTHLH—prostate cancer	1.17e-05	0.000144	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—TGFBR1—prostate cancer	1.17e-05	0.000144	CbGpPWpGaD
Dobutamine—CA2—Metabolism—PTGS2—prostate cancer	1.16e-05	0.000143	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—AKR1C3—prostate cancer	1.15e-05	0.000142	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—PRKACB—prostate cancer	1.15e-05	0.000141	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—PTHLH—prostate cancer	1.15e-05	0.000141	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—TGFBR1—prostate cancer	1.15e-05	0.000141	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—AKR1C3—prostate cancer	1.13e-05	0.000139	CbGpPWpGaD
Dobutamine—COMT—Metabolism—PIK3CD—prostate cancer	1.13e-05	0.000139	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—PRKACB—prostate cancer	1.12e-05	0.000138	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—THBS1—prostate cancer	1.12e-05	0.000138	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—PPP3CA—prostate cancer	1.12e-05	0.000138	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—ANXA1—prostate cancer	1.1e-05	0.000136	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—PPP3CA—prostate cancer	1.09e-05	0.000135	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—THBS1—prostate cancer	1.09e-05	0.000135	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—PRKCZ—prostate cancer	1.08e-05	0.000133	CbGpPWpGaD
Dobutamine—CA5A—Metabolism—PIK3CA—prostate cancer	1.08e-05	0.000133	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—ANXA1—prostate cancer	1.08e-05	0.000133	CbGpPWpGaD
Dobutamine—COMT—Metabolism—NOS3—prostate cancer	1.06e-05	0.000131	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—PRKCZ—prostate cancer	1.06e-05	0.00013	CbGpPWpGaD
Dobutamine—ADRB1—GPCR downstream signaling—PIK3CG—prostate cancer	1.06e-05	0.00013	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—PARP1—prostate cancer	1.04e-05	0.000129	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—FGFR4—prostate cancer	1.04e-05	0.000129	CbGpPWpGaD
Dobutamine—ADRB2—GPCR downstream signaling—PIK3CG—prostate cancer	1.03e-05	0.000127	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—CALCA—prostate cancer	1.03e-05	0.000127	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—FGFR4—prostate cancer	1.02e-05	0.000126	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—PARP1—prostate cancer	1.02e-05	0.000126	CbGpPWpGaD
Dobutamine—CA2—Metabolism—PTEN—prostate cancer	1.01e-05	0.000125	CbGpPWpGaD
Dobutamine—CA5B—Metabolism—PIK3CA—prostate cancer	1.01e-05	0.000124	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—CALCA—prostate cancer	1.01e-05	0.000124	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—CXCL12—prostate cancer	1.01e-05	0.000124	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—CXCL12—prostate cancer	9.86e-06	0.000122	CbGpPWpGaD
Dobutamine—COMT—Metabolism—PIK3CB—prostate cancer	9.83e-06	0.000121	CbGpPWpGaD
Dobutamine—COMT—Metabolism—PTGS2—prostate cancer	9.74e-06	0.00012	CbGpPWpGaD
Dobutamine—CA2—Metabolism—EP300—prostate cancer	9.66e-06	0.000119	CbGpPWpGaD
Dobutamine—ADRB1—Signaling by GPCR—PIK3CG—prostate cancer	9.6e-06	0.000118	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—CASP9—prostate cancer	9.49e-06	0.000117	CbGpPWpGaD
Dobutamine—ADRB2—Signaling by GPCR—PIK3CG—prostate cancer	9.39e-06	0.000116	CbGpPWpGaD
Dobutamine—ADRB1—GPCR downstream signaling—PIK3CD—prostate cancer	9.29e-06	0.000115	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—CASP9—prostate cancer	9.28e-06	0.000114	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—PRKCQ—prostate cancer	9.19e-06	0.000113	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—NGFR—prostate cancer	9.19e-06	0.000113	CbGpPWpGaD
Dobutamine—ADRB2—GPCR downstream signaling—PIK3CD—prostate cancer	9.09e-06	0.000112	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—MAP3K7—prostate cancer	9.08e-06	0.000112	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—PRKCQ—prostate cancer	8.99e-06	0.000111	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—NGFR—prostate cancer	8.99e-06	0.000111	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—MAP3K7—prostate cancer	8.89e-06	0.00011	CbGpPWpGaD
Dobutamine—CA5A—Metabolism—AKT1—prostate cancer	8.83e-06	0.000109	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—FGF10—prostate cancer	8.74e-06	0.000108	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—ADRB2—prostate cancer	8.64e-06	0.000107	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—FGF10—prostate cancer	8.55e-06	0.000105	CbGpPWpGaD
Dobutamine—ADRB1—GPCR downstream signaling—JAK2—prostate cancer	8.53e-06	0.000105	CbGpPWpGaD
Dobutamine—ADRB1—Signaling by GPCR—MAP2K1—prostate cancer	8.49e-06	0.000105	CbGpPWpGaD
Dobutamine—COMT—Metabolism—PTEN—prostate cancer	8.49e-06	0.000105	CbGpPWpGaD
Dobutamine—ADRB1—Signaling by GPCR—PIK3CD—prostate cancer	8.44e-06	0.000104	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—VAV3—prostate cancer	8.43e-06	0.000104	CbGpPWpGaD
Dobutamine—ADRB2—GPCR downstream signaling—JAK2—prostate cancer	8.34e-06	0.000103	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—TGFBR2—prostate cancer	8.31e-06	0.000102	CbGpPWpGaD
Dobutamine—ADRB2—Signaling by GPCR—MAP2K1—prostate cancer	8.31e-06	0.000102	CbGpPWpGaD
Dobutamine—ADRB2—Signaling by GPCR—PIK3CD—prostate cancer	8.25e-06	0.000102	CbGpPWpGaD
Dobutamine—CA5B—Metabolism—AKT1—prostate cancer	8.25e-06	0.000102	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—VAV3—prostate cancer	8.25e-06	0.000102	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—ITPR1—prostate cancer	8.18e-06	0.000101	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—TGFBR2—prostate cancer	8.13e-06	0.0001	CbGpPWpGaD
Dobutamine—COMT—Metabolism—EP300—prostate cancer	8.1e-06	9.98e-05	CbGpPWpGaD
Dobutamine—ADRB1—GPCR downstream signaling—PIK3CB—prostate cancer	8.1e-06	9.98e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—ITPR1—prostate cancer	8e-06	9.86e-05	CbGpPWpGaD
Dobutamine—ADRB2—GPCR downstream signaling—PIK3CB—prostate cancer	7.92e-06	9.77e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—IGF1R—prostate cancer	7.82e-06	9.64e-05	CbGpPWpGaD
Dobutamine—ADRB1—GPCR downstream signaling—CXCL8—prostate cancer	7.78e-06	9.59e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling by GPCR—JAK2—prostate cancer	7.74e-06	9.55e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—IGF1R—prostate cancer	7.65e-06	9.43e-05	CbGpPWpGaD
Dobutamine—ADRB2—GPCR downstream signaling—CXCL8—prostate cancer	7.61e-06	9.39e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling by GPCR—JAK2—prostate cancer	7.57e-06	9.34e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—LPL—prostate cancer	7.49e-06	9.24e-05	CbGpPWpGaD
Dobutamine—ADRB1—GPCR downstream signaling—IL2—prostate cancer	7.44e-06	9.17e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—PDGFRB—prostate cancer	7.43e-06	9.16e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling by GPCR—PIK3CB—prostate cancer	7.35e-06	9.07e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—LPL—prostate cancer	7.33e-06	9.04e-05	CbGpPWpGaD
Dobutamine—ADRB2—GPCR downstream signaling—IL2—prostate cancer	7.28e-06	8.97e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—PDGFRB—prostate cancer	7.27e-06	8.96e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—ITGB3—prostate cancer	7.24e-06	8.92e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling by GPCR—PIK3CB—prostate cancer	7.19e-06	8.87e-05	CbGpPWpGaD
Dobutamine—CA2—Metabolism—PIK3CA—prostate cancer	7.15e-06	8.81e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—ITGB3—prostate cancer	7.08e-06	8.73e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling by GPCR—CXCL8—prostate cancer	7.07e-06	8.71e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—ERBB3—prostate cancer	7.02e-06	8.66e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—FGFR2—prostate cancer	7.01e-06	8.64e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling by GPCR—CXCL8—prostate cancer	6.91e-06	8.52e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—ERBB3—prostate cancer	6.87e-06	8.47e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—FGFR2—prostate cancer	6.86e-06	8.45e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling by GPCR—IL2—prostate cancer	6.75e-06	8.33e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—TERT—prostate cancer	6.73e-06	8.3e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling by GPCR—IL2—prostate cancer	6.61e-06	8.14e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—TERT—prostate cancer	6.58e-06	8.12e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—HIF1A—prostate cancer	6.44e-06	7.93e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—HIF1A—prostate cancer	6.3e-06	7.76e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—LEP—prostate cancer	6.28e-06	7.74e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—CAV1—prostate cancer	6.22e-06	7.67e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—KDR—prostate cancer	6.15e-06	7.59e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—LEP—prostate cancer	6.15e-06	7.58e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—CAV1—prostate cancer	6.09e-06	7.51e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—KDR—prostate cancer	6.02e-06	7.42e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—ESR1—prostate cancer	6e-06	7.39e-05	CbGpPWpGaD
Dobutamine—COMT—Metabolism—PIK3CA—prostate cancer	5.99e-06	7.39e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—ESR1—prostate cancer	5.87e-06	7.23e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—BAD—prostate cancer	5.85e-06	7.22e-05	CbGpPWpGaD
Dobutamine—CA2—Metabolism—AKT1—prostate cancer	5.84e-06	7.2e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—BAD—prostate cancer	5.73e-06	7.06e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—APC—prostate cancer	5.67e-06	6.99e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—PIK3CG—prostate cancer	5.67e-06	6.99e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—IRS1—prostate cancer	5.6e-06	6.91e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—EGF—prostate cancer	5.6e-06	6.91e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—PIK3CG—prostate cancer	5.55e-06	6.84e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—APC—prostate cancer	5.55e-06	6.84e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—IRS1—prostate cancer	5.48e-06	6.76e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—EGF—prostate cancer	5.48e-06	6.76e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—GSK3B—prostate cancer	5.44e-06	6.71e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—INS—prostate cancer	5.37e-06	6.62e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—GSK3B—prostate cancer	5.32e-06	6.56e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—CREBBP—prostate cancer	5.26e-06	6.48e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—INS—prostate cancer	5.25e-06	6.47e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—IGF1—prostate cancer	5.19e-06	6.4e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling by GPCR—EGFR—prostate cancer	5.17e-06	6.37e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—CREBBP—prostate cancer	5.14e-06	6.34e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—IGF1—prostate cancer	5.08e-06	6.26e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling by GPCR—EGFR—prostate cancer	5.05e-06	6.23e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—MAP2K1—prostate cancer	5.02e-06	6.19e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—PIK3CD—prostate cancer	4.98e-06	6.14e-05	CbGpPWpGaD
Dobutamine—ADRB1—GPCR downstream signaling—PIK3CA—prostate cancer	4.94e-06	6.09e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—SERPINE1—prostate cancer	4.93e-06	6.08e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—MAP2K1—prostate cancer	4.91e-06	6.05e-05	CbGpPWpGaD
Dobutamine—COMT—Metabolism—AKT1—prostate cancer	4.89e-06	6.03e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling by GPCR—KRAS—prostate cancer	4.88e-06	6.02e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—PIK3CD—prostate cancer	4.88e-06	6.01e-05	CbGpPWpGaD
Dobutamine—ADRB2—GPCR downstream signaling—PIK3CA—prostate cancer	4.83e-06	5.95e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—SERPINE1—prostate cancer	4.82e-06	5.94e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling by GPCR—KRAS—prostate cancer	4.77e-06	5.88e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—FGF2—prostate cancer	4.77e-06	5.88e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—NOS3—prostate cancer	4.71e-06	5.8e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—FGF2—prostate cancer	4.67e-06	5.76e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—NOS3—prostate cancer	4.6e-06	5.68e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—JAK2—prostate cancer	4.57e-06	5.64e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling by GPCR—PIK3CA—prostate cancer	4.48e-06	5.53e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—JAK2—prostate cancer	4.47e-06	5.52e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—MDM2—prostate cancer	4.47e-06	5.5e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—ERBB2—prostate cancer	4.4e-06	5.43e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling by GPCR—PIK3CA—prostate cancer	4.39e-06	5.41e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—MDM2—prostate cancer	4.37e-06	5.38e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—PIK3CB—prostate cancer	4.34e-06	5.36e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—ERBB2—prostate cancer	4.31e-06	5.31e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—PIK3CB—prostate cancer	4.25e-06	5.24e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—CXCL8—prostate cancer	4.17e-06	5.15e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—CXCL8—prostate cancer	4.08e-06	5.03e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—CDKN1B—prostate cancer	4.08e-06	5.03e-05	CbGpPWpGaD
Dobutamine—ADRB1—GPCR downstream signaling—AKT1—prostate cancer	4.03e-06	4.97e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—CASP3—prostate cancer	4e-06	4.93e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—IL2—prostate cancer	3.99e-06	4.92e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—CDKN1B—prostate cancer	3.99e-06	4.92e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling by GPCR—IL6—prostate cancer	3.97e-06	4.89e-05	CbGpPWpGaD
Dobutamine—ADRB2—GPCR downstream signaling—AKT1—prostate cancer	3.95e-06	4.86e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—CASP3—prostate cancer	3.91e-06	4.82e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—IL2—prostate cancer	3.9e-06	4.81e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—CCND1—prostate cancer	3.89e-06	4.79e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling by GPCR—IL6—prostate cancer	3.88e-06	4.79e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—CTNNB1—prostate cancer	3.85e-06	4.75e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—CCND1—prostate cancer	3.8e-06	4.69e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—MMP9—prostate cancer	3.78e-06	4.66e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—CTNNB1—prostate cancer	3.77e-06	4.64e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—CDKN1A—prostate cancer	3.76e-06	4.64e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—PTEN—prostate cancer	3.75e-06	4.63e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—MMP9—prostate cancer	3.69e-06	4.55e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—CDKN1A—prostate cancer	3.68e-06	4.54e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—PTEN—prostate cancer	3.67e-06	4.53e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling by GPCR—AKT1—prostate cancer	3.66e-06	4.51e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling by GPCR—AKT1—prostate cancer	3.58e-06	4.42e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—EP300—prostate cancer	3.58e-06	4.41e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—EP300—prostate cancer	3.5e-06	4.32e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—SRC—prostate cancer	3.48e-06	4.29e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—SRC—prostate cancer	3.41e-06	4.2e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—VEGFA—prostate cancer	3.39e-06	4.18e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—STAT3—prostate cancer	3.36e-06	4.14e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—VEGFA—prostate cancer	3.32e-06	4.09e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—STAT3—prostate cancer	3.28e-06	4.05e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—MYC—prostate cancer	3.12e-06	3.85e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—TGFB1—prostate cancer	3.11e-06	3.84e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—MYC—prostate cancer	3.05e-06	3.76e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—EGFR—prostate cancer	3.05e-06	3.76e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—TGFB1—prostate cancer	3.04e-06	3.75e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—EGFR—prostate cancer	2.98e-06	3.68e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—KRAS—prostate cancer	2.88e-06	3.55e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—KRAS—prostate cancer	2.82e-06	3.48e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—PIK3CA—prostate cancer	2.65e-06	3.26e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—PIK3CA—prostate cancer	2.59e-06	3.19e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—TP53—prostate cancer	2.56e-06	3.16e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—TP53—prostate cancer	2.51e-06	3.09e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—IL6—prostate cancer	2.35e-06	2.89e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—IL6—prostate cancer	2.29e-06	2.83e-05	CbGpPWpGaD
Dobutamine—ADRB1—Signaling Pathways—AKT1—prostate cancer	2.16e-06	2.67e-05	CbGpPWpGaD
Dobutamine—ADRB2—Signaling Pathways—AKT1—prostate cancer	2.12e-06	2.61e-05	CbGpPWpGaD
